scispace - formally typeset
T

Terho Lehtimäki

Researcher at University of Tampere

Publications -  1375
Citations -  129159

Terho Lehtimäki is an academic researcher from University of Tampere. The author has contributed to research in topics: Population & Genome-wide association study. The author has an hindex of 142, co-authored 1304 publications receiving 106981 citations. Previous affiliations of Terho Lehtimäki include Boston University & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects

TL;DR: Since there is a correlation between the plasma level of timolol and several haemodynamic effects – especially HR in the state of elevated β‐adrenergic tonus – the CYP2D6 poor metabolizers may be more prone to bradycardia during treatment with (aqueous) ophthalmic Timolol.
Journal ArticleDOI

Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals

John D. Eicher, +127 more
TL;DR: The authors' large-scale Exomechip analyses identified previously undocumented associations with platelet traits and further indicate that several complex quantitative hematological, lipid, and cardiovascular traits share genetic factors.
Journal ArticleDOI

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke

TL;DR: Findings in this unique combination of clinical and autopsy data provide evidence that PCSK9 gene associates with the risk of LVA stroke subtype, and suggest that the risk is mediated by the severity of intracranial atherosclerosis.
Journal ArticleDOI

Association of an interleukin 1B gene polymorphism (−511) with Parkinson's disease in Finnish patients

TL;DR: Investigating whether polymorphisms of the IL1 cluster genes are associated with the risk of AD or PD in Finnish patients found some evidence in support of this.
Journal ArticleDOI

Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.

TL;DR: Up-regulated adhesion molecules in blood and CSF indicate sustained potential for inflammation in the CNS throughout the clinical spectrum of MS.